NCT05686239 - A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS) | Biotech Hunter

Enrollment

242

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

April 9, 2025

Study Completion Date

April 9, 2025

Conditions

Cognitive Impairment Associated With Schizophrenia (CIAS)Cognitive ImpairmentSchizophrenia

Interventions

DRUG

RL-007 (Inidascamine)

investigational study drug

DRUG

Placebo

placebo capsules matching the appearance and size of the active drug

Trial Locations (36)

11235

Recognify Research Site, Brooklyn

20877

Recognify Research Site, Gaithersburg

27599

Recognify Research Site, Chapel Hill

30030

Recognify Research Site, Atlanta

30912

Recognify Research Site, Augusta

33016

Recognify Research Site, Hialeah

Recognify Research Site, Miami Lakes

33135

Recognify Research Site, Miami

44122

Recognify Research Site, Cleveland

45219

Recognify Research Site, Cincinnati

75231

Recognify Research Site, Dallas

77074

Recognify Research Site, Houston

90230

Recognify Research Site, Culver City

90502

Recognify Research Site, Torrance

92056

Recognify Research Site, Oceanside

92845

Collaborative Neuroscience Research, Garden Grove

92868

Recognify Research Site, Orange

94549

Recognify Research Site, Lafayette

98201

Recognify Research Site, Everett

08009

Recognify Research Site, Berlin

Unknown

Recognify Research Site, Burgas

Recognify Research Site, Kardzhali

Recognify Research Site, Pleven

Recognify Research Site, Plovdiv

Recognify Research Site, Sofia

Recognify Research Site (a), Varna

Recognify Research Site (b), Varna

Recognify Research Site, Pilsen

Recognify Research Site (a), Prague

Recognify Research Site (b), Prague

Recognify Research Site, Gdansk

Recognify Research Site, Gorlice

Recognify Research Site, Kielce

Recognify Research Site, Lodz

Recognify Research Site, Lublin

Recognify Research Site, Poznan